menu
    • menu
    [{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal Bioventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"RLYB-211","moa":"CD61","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Pivotal Bioventure Partners","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Pivotal Bioventure Partners"},{"orgOrder":0,"company":"Rallybio","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Rallybio","highestDevelopmentStatusID":"3","companyTruncated":"Rallybio \/ Rallybio"},{"orgOrder":0,"company":"Rallybio","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"RLYB-114","moa":"Complement C5","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Rallybio"},{"orgOrder":0,"company":"Rallybio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB-331","moa":"Matriptase-2","graph1":"Hematology","graph2":"Preclinical","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rallybio \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Rallybio"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"RLYB212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"RLYB212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"RLYB212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RLYB-116","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"RLYB-116","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RLYB116","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"REV102","moa":"ENPP1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rallybio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Rallybio \/ Recursion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Recursion Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Rallybio

    Menu

    Rallybio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : REV102

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Recursion Pharma

                            Deal Size : $25.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

                            Details : Rallybio sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP) to Recursion.

                            Product Name : REV102

                            Product Type : Other Small Molecule

                            Upfront Cash : $7.5 million

                            July 08, 2025

                            Lead Product(s) : REV102

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Recursion Pharma

                            Deal Size : $25.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

                            Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 08, 2025

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

                            Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB116

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 28, 2025

                            Lead Product(s) : RLYB116

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

                            Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 21, 2024

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rallybio Starts Phase 2 RLYB212 Trial for Pregnant Women At Risk of FNAIT

                            Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 29, 2024

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $6.6 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rallybio Collaborates on Solutions for Fetal Alloimmune Thrombocytopenia

                            Details : Under this collaboration, Johnson & Johnson will fund Rallybio's RLYB212, the sole investigational therapy aimed at addressing the needs of pregnant individuals at risk of FNAIT.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 04, 2024

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $6.6 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloim...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 30, 2024

                            Lead Product(s) : RLYB212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB-116

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously ...

                            Details : RLYB116 is a novel antibody mimetic fusion protein, long-acting C5 inhibitor. It is being evaluated in phase 1 clinical trials for patients with complement-mediated diseases.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 20, 2023

                            Lead Product(s) : RLYB-116

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Rallybio

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study...

                            Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 28, 2023

                            Lead Product(s) : RLYB-212

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth